Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04724473 · ClinicalTrials.gov registry record · Early Phase 1
A Study Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne Vulgaris
A Early Phase 1 study, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 1,030
- Enrollment target
NCT04724473: Completed Early Phase 1 study, sponsored by Sun Pharmaceutical Industries.
NCT04724473 is a Early Phase 1 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 1,030 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (1843% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04724473, a Early Phase 1 study, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 1,030 participants
- Enrollment target
Study Summary
The bioequivalence and safety of Tretinoin Cream 0.025% (Taro Pharmaceuticals U.S.A, Inc.) and RETIN-A® (Tretinoin) Cream 0.025% in the treatment of acne vulgaris.
Primary Outcome
To evaluate the percentage change in the inflammatory and non-inflammatory lesion counts
Interventions
- DRUG Tretinoin Cream 0.025%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,030 participants |
| Start Date | 2019-12-10 |
| Est. Completion | 2020-11-21 |
| Phase | Early Phase 1 |
What the finished NCT04724473 record still lists
NCT04724473 is an interventional study that assigns participants to a tested intervention. Its 1,030 participants enrollment target places it among the larger protocols in the corpus, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (1843% higher).
The record links to 0 conditions, and to 1 intervention - of which Tretinoin Cream 0.025% is the first listed.
NCT04724473 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04724473 about?
NCT04724473 is a clinical study titled "A Study Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne Vulgaris". The bioequivalence and safety of Tretinoin Cream 0.025% (Taro Pharmaceuticals U.S.A, Inc.) and RETIN-A® (Tretinoin) Cream 0.025% in the treatment of acne vulgaris.
What is the current status of trial NCT04724473?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 1,030 participants. The study started on 2019-12-10. Estimated completion is 2020-11-21.
What interventions are being tested in trial NCT04724473?
The interventions under investigation include: Tretinoin Cream 0.025% (DRUG).
Who is sponsoring clinical trial NCT04724473?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04724473's enrollment target sits among peer trials
1,030 7th of 2000 higher than 1,994 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06080698 · 1,030 participants · NA
Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial
- NCT07084363 · 1,032 participants · NA
Quantitative Versus qUAlitative NeuromoniToring of neUroMuscular Block for Non-cardiothoracic Surgery
- NCT05037682 · 1,035 participants · NA
Pain and Opioid Management in Older Adults
- NCT07282600 · 1,035 participants · Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI